Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724711 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study of Switching From Epzicom to Truvada
A Phase 4 study of HIV Infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 312
- Enrollment target
- 20
- Study locations
NCT00724711: Completed Phase 4 study of HIV Infection, sponsored by Gilead Sciences.
NCT00724711 is a Phase 4 study of HIV Infection that has completed, run by Gilead Sciences. The registered enrollment target is 312 participants, above the 239-participant average among 73 other HIV Infection trials with a reported enrollment target (31% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00724711, a Phase 4 study of HIV Infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 312 participants
- Enrollment target
- 20
- Study locations
Study Summary
This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in virologically suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects maintained on a ritonavir-boosted protease inhibitor (PI/r)-containing antiretroviral (ARV) regimen. Duration of treatment is 48 weeks.
Primary Outcome
The percentage of participants with HIV-1 RNA \< 200 copies/mL based on TLOVR algorithm at Week 48 was summarized. Participants were considered nonresponders in the TLOVR analysis if they experienced virologic rebound prior to or at Week 48, discontinued study before Week 48, or added a new antiretroviral (ARV) agent prior to completion of the study. Virologic rebound was defined as 2 consecutive HIV-1 RNA values \>= 200 copies/mL or the last HIV-1 RNA value \>= 200 copies/mL followed by discont
Conditions Studied
Interventions
- DRUG emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
- DRUG abacavir (ABC)/lamivudine (3TC)
Study Locations (20)
California
- Vista Medical Partners - Beverly Hills
- AHF - Beverly Hills
- Pacific Oaks Medical Group - Beverly Hills
- Center for Special Immunology - Fountain Valley
- Living Hope Clinical Foundation - Long Beach
- Jeffrey Goodman Special Care Clinic - Los Angeles
- Peter J. Ruane, MD, Inc. - Los Angeles
- Anthony M Mills, MD - Los Angeles
- Orange Coast Medical Group - Newport Beach
- Tarzana Treatment Center - Northridge
- Alameda County Medical Center - Oakland
- Health Management Institute, Inc. - San Francisco
- Metropolis Medical - San Francisco
Florida
- Biogenomx Research Institute, LLC - Fort Lauderdale
- Life Way Inc. - Fort Lauderdale
- Therafirst Medical Centers - Fort Lauderdale
- HIV Clinical Research - Fort Lauderdale
Arkansas
- Health For Life Clinic, PLLC - Little Rock
Colorado
- Kaiser Permanente - Denver
Connecticut
- Blick Medical Associates - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
What the finished NCT00724711 record still lists
NCT00724711 is an interventional study that assigns participants to a tested intervention. The registered 312 participants enrollment target is mid-sized for trials with a published cap, above the 239-participant average among 73 other HIV Infection trials with a reported enrollment target (31% higher).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the first listed.
NCT00724711 names 20 study sites across 5 states, led by California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00724711 about?
NCT00724711 is a clinical study titled "Safety and Efficacy Study of Switching From Epzicom to Truvada". This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in virologically suppressed, human immunodeficiency ...
What is the current status of trial NCT00724711?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 312 participants. The study started on 2008-07. Estimated completion is 2011-04.
What conditions does trial NCT00724711 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00724711?
The interventions under investigation include: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (DRUG), abacavir (ABC)/lamivudine (3TC) (DRUG).
Who is sponsoring clinical trial NCT00724711?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00724711 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00724711's enrollment target sits among peer trials
312 14th of 73 higher than 60 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
COMPLETED · Phase 4
-
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
COMPLETED · Phase 4
-
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
COMPLETED · Phase 4
-
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
COMPLETED · Phase 4
-
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia